Skip to main content
MASIMO CORP logo

MASIMO CORP — Investor Relations & Filings

Ticker · MASI ISIN · US5747951003 LEI · 549300Q4A8JK0PIYCU29 US Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2024-07-16 Regulatory Filings
Country US United States of America
Listing US MASI

About MASIMO CORP

https://www.masimo.com/

Masimo is a global medical technology company that develops, manufactures, and markets a wide array of noninvasive patient monitoring technologies. The company's core offering is its proprietary Signal Extraction Technology (SET®) pulse oximetry, renowned for its ability to provide accurate measurements during patient motion and low peripheral perfusion. Masimo's product portfolio also includes advanced solutions for brain function monitoring (SedLine®), regional oximetry (O3®), and integrated patient monitoring and connectivity platforms like Root®. These technologies are designed to improve patient outcomes, enhance patient safety, and streamline clinical workflows in various healthcare settings, including hospitals, emergency medical services, and home care. The company focuses on creating innovative solutions that empower clinicians with reliable data to make critical care decisions.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by Masimo Corporation. It discusses the postponement of the 2024 Annual Meeting of Stockholders, litigation against a shareholder group, and proxy statement updates. It includes no financial statements or detailed financial data but rather regulatory and corporate governance updates related to shareholder meetings and proxy materials. The document is not an Annual Report, Earnings Release, or Management Discussion but a regulatory filing reporting material corporate events and notices. Therefore, it fits best under Regulatory Filings (RNS).
2024-07-16 English
SC 13D/A
Major Shareholding Notification
2024-07-15 English
DFAN14A
Proxy Solicitation & Information Statement
2024-07-15 English
DEFINITIVE ADDITIONAL MATERIALS
Remuneration Information Classification · 95% confidence The document is titled 'DEFA14A' and is described as 'Definitive Additional Materials' related to a Schedule 14A Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It contains detailed information about the company's position regarding a shareholder vote, board nominees, and corporate governance issues ahead of the 2024 Annual Meeting of Stockholders. The content focuses on soliciting votes and providing additional information to shareholders to influence their voting decisions. This type of filing is consistent with Definitive Additional Materials to a Proxy Statement, which falls under the Remuneration Information or Proxy Solicitation & Information Statement categories. Given the form type DEFA14A and the nature of the content, the correct classification is 'DEF 14A' which covers executive compensation and proxy solicitation materials. The document is lengthy (15,000 characters) and contains substantive content, not merely an announcement or certification, so it is not RPA or RNS. Therefore, the filing type code is 'DEF 14A' with high confidence.
2024-07-15 English
DFAN14A
Proxy Solicitation & Information Statement
2024-07-13 English
DFAN14A
Proxy Solicitation & Information Statement
2024-07-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.